Terms ending in 2039
Every in-force patent on Juno Therapeutics Inc.'s record whose computed term ends in 2039, whoever holds it now. Soonest term end first, then patent number.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Holder | Status | Expires | Confidence |
|---|---|---|---|---|---|
| US 11,535,903 | Methods and Reagents for Assessing the Presence or Absence of Replication Competent Virus In force · High confidence | Juno Therapeutics, Inc. | In force | High confidence | |
| US 12,264,371 | Methods and Reagents for Assessing the Presence or Absence of Replication Competent Virus In force · Medium confidence | Juno Therapeutics, Inc. | In force | Medium confidence | |
| US 11,413,310 | Articles of Manufacture and Methods for Treatment Using Adoptive Cell Therapy In force · High confidence | Juno Therapeutics, Inc. | In force | High confidence | |
| US 11,517,627 | Cell Surface Conjugates and Related Cell Compositions and Methods In force · High confidence | C3S2 GmbH | In force | High confidence | |
| US 11,564,946 | Methods Associated with Tumor Burden for Assessing Response to a Cell Therapy In force · High confidence | Juno Therapeutics, Inc. | In force | High confidence | |
| US 11,561,219 | Methods of Enumerating Particles Present in a Cell Composition In force · High confidence | Juno Therapeutics, Inc. | In force | High confidence | |
| US 11,066,475 | Chimeric Antigen Receptors Specific for B-Cell Maturation Antigen and Encoding Polynucleotides In force · High confidence | Juno Therapeutics, Inc. | In force | High confidence | |
| US 12,428,486 | Chimeric Antigen Receptors Specific for B-Cell Maturation Antigen and Encoding Polynucleotides In force · High confidence | Juno Therapeutics, Inc. | In force | High confidence | |
| US 12,031,975 | Methods of Assessing or Monitoring a Response to a Cell Therapy In force · High confidence | Juno Therapeutics, Inc. | In force | High confidence | |
| US 11,896,615 | Immunotherapy Methods and Compositions Involving Tryptophan Metabolic Pathway Modulators In force · High confidence | Juno Therapeutics, Inc. | In force | High confidence | |
| 7 more term ends in 2039 · Pro | |||||
10 of 17 patents shown. Soonest term end first, then patent number.
Pro members see all 17.
14 of these are in force and held by Juno Therapeutics Inc..
Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.